Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Monday morning. The firm issued a hold rating on the stock.

Several other research analysts have also commented on the stock. HC Wainwright reduced their price objective on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Lake Street Capital reduced their price target on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th.

Ekso Bionics Stock Up 5.4 %

Ekso Bionics stock opened at $0.77 on Monday. Ekso Bionics has a twelve month low of $0.50 and a twelve month high of $3.03. The business has a fifty day moving average of $0.71 and a two-hundred day moving average of $0.97. The firm has a market cap of $16.93 million, a P/E ratio of -1.18 and a beta of 1.47. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The company had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same quarter last year, the company earned ($0.24) earnings per share. On average, analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.